End-of-day quote
INDONESIA S.E.
06:00:00 2024-07-10 pm EDT
|
5-day change
|
1st Jan Change
|
2,050
IDR
|
+1.49%
|
|
+4.59%
|
+11.72%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
6,255,000
|
6,277,500
|
6,300,000
|
6,764,796
|
6,358,909
|
8,275,601
|
Enterprise Value (EV)
1 |
4,816,403
|
4,540,048
|
4,335,777
|
4,918,675
|
4,222,487
|
5,522,412
|
P/E ratio
|
12.2
x
|
11.3
x
|
8
x
|
8.2
x
|
6.35
x
|
7.03
x
|
Yield
|
2.88%
|
3.58%
|
4.29%
|
4.67%
|
8.87%
|
6.81%
|
Capitalization / Revenue
|
0.62
x
|
0.57
x
|
0.57
x
|
0.6
x
|
0.52
x
|
0.63
x
|
EV / Revenue
|
0.48
x
|
0.41
x
|
0.4
x
|
0.44
x
|
0.34
x
|
0.42
x
|
EV / EBITDA
|
5.31
x
|
4.46
x
|
3.33
x
|
3.79
x
|
4.52
x
|
4.09
x
|
EV / FCF
|
-43.2
x
|
10.3
x
|
11.8
x
|
42.2
x
|
324
x
|
7.43
x
|
FCF Yield
|
-2.32%
|
9.71%
|
8.48%
|
2.37%
|
0.31%
|
13.5%
|
Price to Book
|
1.22
x
|
1.14
x
|
1.04
x
|
1.04
x
|
0.88
x
|
1.08
x
|
Nbr of stocks (in thousands)
|
4,500,000
|
4,500,000
|
4,500,000
|
4,509,864
|
4,509,864
|
4,509,864
|
Reference price
2 |
1,390
|
1,395
|
1,400
|
1,500
|
1,410
|
1,835
|
Announcement Date
|
3/29/19
|
4/1/20
|
3/31/21
|
3/31/22
|
3/24/23
|
3/28/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
10,088,119
|
10,993,842
|
10,968,402
|
11,234,443
|
12,254,369
|
13,119,785
|
EBITDA
1 |
907,580
|
1,017,689
|
1,301,141
|
1,297,800
|
933,588
|
1,350,964
|
EBIT
1 |
702,576
|
797,080
|
1,075,647
|
1,104,347
|
728,658
|
1,079,831
|
Operating Margin
|
6.96%
|
7.25%
|
9.81%
|
9.83%
|
5.95%
|
8.23%
|
Earnings before Tax (EBT)
1 |
727,700
|
796,221
|
1,064,449
|
1,098,370
|
1,329,823
|
1,603,164
|
Net income
1 |
512,029
|
554,263
|
787,803
|
823,768
|
1,001,628
|
1,177,432
|
Net margin
|
5.08%
|
5.04%
|
7.18%
|
7.33%
|
8.17%
|
8.97%
|
EPS
2 |
113.8
|
123.2
|
175.1
|
183.0
|
222.0
|
261.0
|
Free Cash Flow
1 |
-111,501
|
440,624
|
367,844
|
116,568
|
13,021
|
743,613
|
FCF margin
|
-1.11%
|
4.01%
|
3.35%
|
1.04%
|
0.11%
|
5.67%
|
FCF Conversion (EBITDA)
|
-
|
43.3%
|
28.27%
|
8.98%
|
1.39%
|
55.04%
|
FCF Conversion (Net income)
|
-
|
79.5%
|
46.69%
|
14.15%
|
1.3%
|
63.16%
|
Dividend per Share
2 |
40.00
|
50.00
|
60.00
|
70.00
|
125.0
|
125.0
|
Announcement Date
|
3/29/19
|
4/1/20
|
3/31/21
|
3/31/22
|
3/24/23
|
3/28/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,438,597
|
1,737,452
|
1,964,223
|
1,846,122
|
2,136,422
|
2,753,189
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-111,501
|
440,624
|
367,844
|
116,568
|
13,021
|
743,613
|
ROE (net income / shareholders' equity)
|
10.3%
|
10.6%
|
13.7%
|
13.2%
|
14.4%
|
16%
|
ROA (Net income/ Total Assets)
|
5.74%
|
6.13%
|
7.69%
|
7.36%
|
4.34%
|
5.96%
|
Assets
1 |
8,923,315
|
9,035,767
|
10,240,386
|
11,188,395
|
23,064,631
|
19,753,246
|
Book Value Per Share
2 |
1,142
|
1,219
|
1,346
|
1,448
|
1,600
|
1,707
|
Cash Flow per Share
2 |
423.0
|
501.0
|
588.0
|
596.0
|
773.0
|
819.0
|
Capex
1 |
466,219
|
328,688
|
447,837
|
385,870
|
592,167
|
326,651
|
Capex / Sales
|
4.62%
|
2.99%
|
4.08%
|
3.43%
|
4.83%
|
2.49%
|
Announcement Date
|
3/29/19
|
4/1/20
|
3/31/21
|
3/31/22
|
3/24/23
|
3/28/24
|
|
1st Jan change
|
Capi.
|
---|
| +11.72% | 571M | | +60.25% | 841B | | +39.01% | 625B | | -4.49% | 360B | | +18.30% | 327B | | +9.64% | 300B | | +15.08% | 242B | | +3.72% | 228B | | +18.16% | 227B | | +12.87% | 174B |
Other Pharmaceuticals
|